Impact Factor
3.84
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.81
828 total citations
h5-index
38
h5 depth signal
Cited share
82.0%
155 of 189
Total citations
828
Citation footprint
Metric signal
4.11
External metric anchor
Self-citation
2.3%
19 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
398
China
140
United Kingdom
135
Italy
133
Germany
110
Citing Fields of Research
Endocrinology & Metabolism
421
Oncology
300
Gut-Brain Axis Disorders
254
Adrenal Dysfunction
193
Breast Cancer
145
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,012
Articles tracked across the journal lifetime
Indexed publication set
189
155 cited publications
Last 12 months
144
12.0 publications/month
Open access share
38.9%
56 OA publications in the last year
Leading citing country
United States
398 citing publications
Leading citing field
Endocrinology & Metabolism
421 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v6n1, Mar. 1999-
v6n1, Mar. 1999-
Active Coverage
Research Focus & Classification
Indexed Subjects
Endocrinology & Metabolism
Adrenal Dysfunction
Gut-Brain Axis Disorders
Oncology
Prostate Cancer
Issuing & Sponsoring Bodies
Contributor
Society for Endocrinology
Broad Categories
Endocrinology
Neoplasms
Endocrinology & Metabolism
Gut-Brain Axis Disorders
Adrenal Dysfunction
MeSH Descriptors
Endocrine System Diseases
Hormones
Paraneoplastic Endocrine Syndromes
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1530/erc-26-0338
Open DOI
Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis
Background: Streptozotocin (STZ)-based chemotherapy remains a treatment option for advanced pancreatic neuroendocrine tumours (PanNETs), particularly when tumour shrinkage is a therapeutic priority. However, its activity has been reporte...
02
DOI 10.1530/erc-26-0280
Open DOI
Immunomodulatory actions of catecholamines, cluster-specific signaling pathways, and metabolites in pheochromocytoma and paraganglioma
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms with an exceptionally high genetic contribution, often driven by single high-penetrance mutations. Approximately one third of patients harbor germline mutatio...
03
DOI 10.1530/erc-26-0317
Open DOI
New Horizons in Pharmacotherapy for Cushing’s Disease and Acromegaly
The recent development of new medical therapies has transformed Cushing’s disease and acromegaly management, offering patients more individualized and effective treatment strategies beyond surgery and also addressing unmet clinical needs...
04
DOI 10.1530/erc-26-0201
Open DOI
Tyrosine Kinase Inhibitors in Metastatic Pheochromocytomas and Paragangliomas: An Updated Systematic Review and Meta-Analysis
Therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) remain limited. Recent studies indicate tyrosine kinase inhibitors (TKIs) offer a promising treatment approach. This study aims to evaluate the efficacy and saf...
05
DOI 10.1530/erc-25-0514
Open DOI
Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common genetic syndrome causing neuroendocrine tumours (NET) with metastatic duodenopancreatic NET (dpNET) forming the predominant cause of MEN1-related mortality. Pept...
06
DOI 10.1530/erc-26-0049
Open DOI
MIB2-mediated ubiquitination of HK2 inhibits glycolysis in PTC
Papillary thyroid carcinoma (PTC), the most common endocrine malignancy, frequently exhibits invasive behaviors including tumor invasion and cervical lymph node metastasis, which serve as major determinants of prognosis. However, reliabl...
07
DOI 10.1530/erc-26-0198
Open DOI
Cancer-Associated Fibroblasts Drive Papillary Thyroid Cancer Progression through ROS/NF-κB/IL-6 Signaling in Hypoxic Microenvironment
Cancer-associated fibroblasts (CAFs) are key components of the tumour microenvironment (TME) in papillary thyroid carcinoma (PTC) and play a critical role in disease progression. We previously reported that interleukin-6 (IL-6) promotes ...
08
DOI 10.1530/erc-26-0243
Open DOI
Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma
Historically, the study of cellular metabolism and the cellular proteome have largely focused on specific proteins and metabolites in certain cellular pathways. With the advent of new “omics” technologies, researchers have been able to p...
09
DOI 10.1530/erc-26-0210
Open DOI
Risk factors for subsequent thyroid neoplasms development in childhood cancer survivors
Subsequent thyroid carcinomas (STC) are common after childhood cancer treatment and have well-described risk factors, whereas information on subsequent thyroid adenomas (STA) remains limited. This study compared treatment-related risk fa...
10
DOI 10.1530/erc-26-0283
Open DOI
Effects of a GLP-1 agonist and antidiabetic therapies on pheochromocytoma/paraganglioma growth
A high proportion of patients with pheochromocytomas and paragangliomas (PPGLs) show glycemic dysregulation. However, studies on the effects of antidiabetic drugs on PPGL tumor growth are still lacking. We evaluated the effects of glucag...
Bibliographical & Catalog Notes
Called also: ERC.
Also available online.
Vol. 3 no. 1 (1996)19990805 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper